Page 5 - Early Stage Development News Today

CHEYENNE, Wyo., May 3, 2023 /PRNewswire/ -- U.S. Gold Corp. is pleased to announce that its Vice President - Exploration and Technical Services, Kevin Francis, will be featured on a panel... | May 3, 2023

2022 was a year of transformation and change:reported $412.5 million in total revenue for the year ended December 31, 2022;reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021;reported $492.2 million in cash resources as of December 31, 2022, w...

/PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or...

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years.

New assay bringsvalidated HRD technology from Myriad Geneticsto the Illumina TruSight Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 23, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upo...

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

Company reports revenues of EUR 13.4 million for the year ended December 31, 2021 As of December 31, 2021, cash and cash equivalents were EUR 32.3 million (USD 36.6 million) TWYMEEG

/PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal...

/PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal...